Ranibizumab (& biosimilar Ongavia)

BNF:
11.8.2
Status:
Do Not Prescribe (DNP), Red
Decision Date:
None
 

Comments

RED: 

  • NICE TA155: treatment of age-related macular degeneration (decision date - 2008)
  • NICE TA274: treating diabetic macular oedema (decision date - March 2013)
  • NICE TA283: treating visual impairment caused by macular secondary to retinal vein occlusion (decision date - July 2013)
  • NICE TA298: treating chorodial neovascularisation associated with pathological myopia (decision date - December 2013)

DO NOT PRESCRIBE (DNP):

  • NICE TA637: diabetic retinopathy (terminated appraisal) (Decision date - July 2020) 

 

 

Do Not Prescribe (DNP) Drug Classifications

  • 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

  • 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
  • 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app